More EGM and outcomes data are needed and a prospective, randomized, controlled trial, FLOW-AF (NCT 04,473,963), is currently being completed to collect additional data on EGF source phenotypes, the ability to identify and acutely eliminate relevant sources and potentially improve clinical outcomes across a population of persistent and long-standing persistent AF patients enrolled at multiple centers. The gene discussed is EGF; the disease is atrial fibrillation.